Human IL-10 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.35 pg/ml(50 μl);0.61 pg/ml (10 μl) |
| Standard Curve Range | 15.63~1000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 3 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0268 | 0.0259 | 0.0264 | |
| 15.63 | 0.0433 | 0.0397 | 0.0415 | 0.0152 |
| 31.25 | 0.0795 | 0.0831 | 0.0813 | 0.0550 |
| 62.50 | 0.1977 | 0.1791 | 0.1884 | 0.1621 |
| 125.00 | 0.4669 | 0.4558 | 0.4614 | 0.4350 |
| 250.00 | 1.1354 | 1.2026 | 1.1690 | 1.1427 |
| 500.00 | 2.7050 | 2.7878 | 2.7464 | 2.7201 |
| 1000.00 | 3.5502 | 3.5608 | 3.5555 | 3.5292 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 16.87 | 106.92 | 324.44 | 17.85 | 99.67 | 293.71 |
| Standard Deviation | 1.07 | 4.78 | 11.70 | 1.34 | 7.33 | 20.34 |
| Coefficient of Variation(%) | 6.3 | 4.5 | 3.6 | 7.5 | 7.4 | 6.9 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested Twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human IL-10 into health human serum sample. The un-spiked serum was used as blank in these experiments.
The recovery ranged from 94% to 109% with an overall mean recovery of 101%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 3.07-8.49 | 100 | 5.19 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-10 in this assay. No medical histories were available for the donors.
n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: IL-10
Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor (CSIF), is the charter member of the IL-10 alpha -helical cytokine family that also includes IL-19, IL-20, IL-22, IL-24, and IL-26/AK155. IL-10 is secreted by many activated hematopoietic cell types as well as hepatic stellate cells, keratinocytes, and placental cytotrophoblasts. Whereas human IL-10 is active on mouse cells, mouse IL-10 does not act on human cells. Mature mouse IL-10 shares 85% amino acid sequence identity with rat IL-10 and 70-77% with bovine, canine, equine, feline, human, ovine, and porcine IL-10. It contains two intrachain disulfide bridges and is expressed as a 36 kDa noncovalently-associated homodimer.
IL-10 mediates its biological activities through a heteromeric receptor complex composed of the type II cytokine receptor subunits IL-10 R alpha and IL-10 R beta. IL-10 R alpha is a 110 kDa transmembrane glycoprotein that is expressed on lymphocytes, NK cells, macrophages, monocytes, astrocytes, intestinal epithelial cells, cytotrophoblasts, and activated hepatic stellate cells, while the 75 kDa transmembrane IL-10 R beta is widely expressed. The IL-10 dimer binds to two IL 10 R alpha chains, triggering recruitment of two IL-10 R beta chains. IL-10 R beta does not bind IL-10 directly but is required for signal transduction. IL-10 R beta also associates with IL-20 R alpha, IL-22 R alpha 1, or IL-28 R alpha to form the receptor complexes for IL-22, IL-26, IL-28, and IL-29.
The involvement of IL-10 in immunoregulation includes both suppressive and stimulatory effects. It functions as an anti-inflammatory cytokine by inhibiting the expansion and activation of Th1 cells and Th17 cells and by promoting the development of M2 macrophages. Its expression by immunosuppressive regulatory T cells (Treg) and regulatory B cells is important for Treg proliferation. Within a tumor microenvironment, however, IL-10 inhibits the expansion of Treg as well as myeloid-derived suppressor cells. IL-10 induces the intratumoral accumulation and activation of CD8+ T cells. IL-10 exerts protective effects including limiting tissue damage in arthritic inflammation and promoting muscle regeneration after injury, but it also contributes to the persistence of viral infections. The levels of IL-10 are elevated in Sjogren's syndrome (saliva), primary CNS lymphoma (cerebrospinal fluid), and ovarian cancer (serum and ascites). Its levels are decreased in the serum in patients with recurrent heart attacks or during preeclampsia and also in the seminal fluid of infertile men.
Under construction!
Under construction!
Under construction!
Citations
-
A ceramic microbridge microfluidic chip to study osteogenic differentiation of mesenchymal stem cells in bioactive ceramic immune microenvironment
Applications: ELISA
Reactivity: Human
Publish Date: 2024 Dec
-
Indoleamine 2,3-dioxygenase 1 alters the proportions of B cell subpopulations in the microenvironment of acute myeloid leukemia
Applications: ELISA
Reactivity: Human
Publish Date: 2025 Apr
-
Multi-omics insights of immune cells in the risk and prognosis of idiopathic membranous nephropathy
Applications: ELISA
Reactivity: Human
Publish Date: 2025 Aug
-
MIR4435–2HG promotes breast cancer evolution through miR-205-5p/UBE2N axis and exosome-mediated macrophage M2-like polarization
Applications: ELISA
Reactivity: Human
Publish Date: 2025 Nov
-
miR-324-3p Drives Malignant Behaviors of Tumor Cells by Promoting M2 Macrophage Polarization in Laryngeal Squamous Cell Carcinoma
Applications: ELISA
Reactivity: Human
Publish Date: 2026 Mar
-
Framework nucleic acids as structural nanomedicine for alleviating multi-organ injury in sepsis
Applications: ELISA
Reactivity: Human
Publish Date: 2026 Aug
-
The TPx Protein of Cysticercus cellulosae Promotes an IL-10–Producing Regulatory B Cell Phenotype in Human B Lymphoblastoid Cells via the cAMP/CREB Pathway
Applications: ELISA
Reactivity: Human
Publish Date: 2026 Aug
